Finance

Beta
Lists
CGEN:NASDAQ
Compugen Ltd
၂.၂၈ US$
+၇.၀၄%
(+၀.၁၅) 1D
၂.၂၈ US$
၀.၀၀% (၀.၀၀)
After hours
Closed: ဇူ ၂, GMT-၄ ၁၆:၀၀:၀၁  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CGEN...
Open
၂.၁၂ US$
High
၂.၃၀ US$
Low
၂.၁၂ US$
Mkt. cap
၂၁.၅၆ ကုဋေ
Avg. vol.
၄.၂၃ သိန်း
Volume
၄.၉၄ သိန်း
P/E ratio
၆.၃၆
52-wk high
၃.၂၄ US$
52-wk low
၁.၃၀ US$
EPS
၀.၃၆ US$
Beta
၂.၇၆
Shares outstanding
၉.၄၆ ကုဋေ
No. of employees
၇၅
Open
၂.၁၂ US$
High
၂.၃၀ US$
Low
၂.၁၂ US$
Mkt. cap
၂၁.၅၆ ကုဋေ
Avg. vol.
၄.၂၃ သိန်း
Volume
၄.၉၄ သိန်း
P/E ratio
၆.၃၆
52-wk high
၃.၂၄ US$
52-wk low
၁.၃၀ US$
EPS
၀.၃၆ US$
Beta
၂.၇၆
Shares outstanding
၉.၄၆ ကုဋေ
No. of employees
၇၅
News stories
From sources across the web
Stock Titan
Stock Titan
·
ပြီးခဲ့သည့် ၁၅ မိနစ်
Outset Medical awards stock to three new hires, including EVP Derick Elliott
Proactive financial news
Proactive financial news
·
ပြီးခဲ့သည့် ၂၃ မိနစ်
Jersey Mike's Subs files for IPO, targets NYSE listing
Yahoo Finance
Yahoo Finance
·
ပြီးခဲ့သည့် ၂၃ မိနစ်
Unpacking Q1 Earnings: Byrna (NASDAQ:BYRN) In The Context Of Other Aerospace and Defense Stocks
Profile
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors. Wikipedia
About Compugen Ltd
CEOAnat Cohen-Dayag
Employees၇၅
Founded၁၉၉၃ ဖေ ၁၀
Headquarters-
Sector-
Websitecgen.com
Analyst ratings
Based on 3 analysts giving stock ratings to CGEN in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for CGEN in the last 3 months.
Highest
Current ၂.၂၈ US$
၅.၀၀ US$ (+၁၁၉.၃၀%)
Average
၄.၆၇ US$ (+၁၀၄.၈၂%)
Lowest
၄.၀၀ US$ (+၇၅.၄၄%)
Analyst
Recommendation
Action
Price target
Projected
Date
Chad Messer
Lake Street
Buy
Reiterated
၅.၀၀ US$
+၁၁၉.၃%
06/24/2026
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
၄.၀၀ US$
+၇၅.၄%
06/04/2026
Daina Graybosch
Leerink Partners
Buy
Maintained
၅.၀၀ US$
+၁၁၉.၃%
05/21/2026
Asthika Goonewardene
Truist Financial
Buy
Reiterated
၄.၀၀ US$
+၇၅.၄%
03/03/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
၄.၀၀ US$
+၇၅.၄%
10/14/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
၂၀၂၅ ဇွန်
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
Revenue
၁.၂၆ သန်း
၁.၈၉ သန်း
၆.၇၃ ကုဋေ
၂.၁၈ သန်း
Cost of goods sold
၁.၆၆ သန်း
၁.၆၅ သန်း
၃.၅၄ သန်း
၁.၈၂ သန်း
Cost of revenue
၁.၆၆ သန်း
၁.၆၅ သန်း
၃.၅၄ သန်း
၁.၈၂ သန်း
Research and development expenses
၅.၆၄ သန်း
၅.၈၀ သန်း
၅.၅၄ သန်း
၆.၉၄ သန်း
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၂.၃၈ သန်း
၂.၃၃ သန်း
၂.၂၁ သန်း
၂.၄၃ သန်း
Operating expense
၈.၀၂ သန်း
၈.၁၃ သန်း
၇.၇၅ သန်း
၉.၃၇ သန်း
Total operating expenses
၉.၆၉ သန်း
၉.၇၈ သန်း
၁.၁၃ ကုဋေ
၁.၁၂ ကုဋေ
Operating income
-၈.၄၃ သန်း
-၇.၈၉ သန်း
၅.၆၀ ကုဋေ
-၉.၀၂ သန်း
Other non operating income
-
-
-၂.၈၀ သောင်း
-
EBT including unusual items
-၇.၃၆ သန်း
-၆.၉၄ သန်း
၅.၆၈ ကုဋေ
-၇.၆၆ သန်း
EBT excluding unusual items
-၇.၃၆ သန်း
-၆.၉၄ သန်း
၅.၆၃ ကုဋေ
-၇.၆၆ သန်း
Income tax expense
-၁.၇၀ သောင်း
၄.၀၀ သောင်း
-
၅.၀၀ ထောင်
Effective tax rate
၀.၂၃%
-၀.၅၈%
-
-၀.၀၇%
Other operating expenses
-
-
-
-
Net income
-၇.၃၄ သန်း
-၆.၉၈ သန်း
၅.၆၈ ကုဋေ
-၇.၆၇ သန်း
Net profit margin
-၅၈၄.၀၉%
-၃၆၉.၀၆%
၈၄.၄၂%
-၃၅၂.၄၄%
Earnings per share
-၀.၀၈
-၀.၀၇
၀.၆၀
-၀.၀၈
Interest and investment income
၁.၀၇ သန်း
၉.၅၄ သိန်း
၆.၃၆ သိန်း
၁.၃၅ သန်း
Interest expense
-
-
-
-
Net interest expenses
၁.၀၇ သန်း
၉.၅၄ သိန်း
၆.၃၆ သိန်း
၁.၃၅ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၈.၃၁ သန်း
-၇.၇၇ သန်း
၅.၆၂ ကုဋေ
-၈.၉၀ သန်း
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create portfolio
Deep Search
AI content may include mistakes. Learn more